2011-12-22 11:00 Aprea Stockholm, Sweden – December 22, 2011. Aprea AB announces that Peter Buhl Jensen has been elected as a new member of the board. Peter Buhl Jensen is Professor in Clinical Oncology at Copenhagen University, MD, DMSc and former Chief Oncologist at the Department of Oncology, Ålborg Hospital.

2011-09-09 14:15 Aprea Stockholm, Sweden – September 9, 2011. Aprea AB today announced that it has secured SEK 20.4m (EUR 2.1m) which will allow the company to complete its planned continuation of its clinical study with APR-246 in patients with hematologic malignancies. The company also announced that Torbjörn Bjerke has been elected as a new member of the board.

2010-11-08 16:00 Aprea Stockholm, Sweden – November 8, 2010. Aprea AB today announced that encouraging data from its preclinical studies with APR-246 will be presented in a poster session at the upcoming 52nd ASH (American Society of Hematology) Annual Meeting and Exposition in Orlando, FL, USA, December 4-7, 2010.

2010-09-30 11:36 Aprea Ulf Björklund har utsetts till VD för Aprea AB. Han tillträder i oktober. Idag är Ulf Björklund VD för OxyPharma AB. Ulf Björklund har lång erfarenhet av läkemedelsbranschen. Innan Ulf började på OxyPharma 2002 arbetade han över 15 år inom Pharmacia. Apreas läkemedelskandidat APR-246 är i slutfasen av en Fas I-studie i cancerpatienter och man planerar under senare delen av 2011 gå in i Fas II.

2010-09-30 11:30 Aprea Ulf Björklund has been appointed new CEO of Aprea and will start in October. Ulf Björklund is today CEO of OxyPharma. Ulf Björklund has a long experience from the pharmaceutical industry. Prior to joining OxyPharma 2002 Ulf spent more then 15 years with Pharmacia. Aprea is in the end of a Phase I study with the candidate drug APR-246 and is planning to start a Phase II study during the fall 2011.

2010-06-08 16:25 Cobra Biologics Unitech Pharma får fortsatt förtroende att tillverka Apreas läkemedelskandidat APR-246 enligt högt ställda GMP-krav.

2010-06-08 16:21 Cobra Biologics Unitech Pharma AB announces today that it will provide Aprea AB with additional GMP manufacturing of APR-246. APR-246 is Aprea’s first candidate drug which is undergoing a Phase I clinical study for refractory hematological malignancies and prostate cancer patients in Sweden.

2010-02-18 12:03 Aprea Stockholm, Sverige – 18 februari 2010. Aprea, ett företag som arbetar med forskning och utveckling av cancerläkemedel, tillkännagav idag att den europeiska läkemedelsmyndigheten, EMA, har givit ett positivt utlåtande och rekommenderar att den europeiska kommissionen ger Apreas läkemedelskandidat APR-246 särläkemedelsstatus (Orphan Drug Designation) för behandling av akut myeloid leukemi (AML).

2010-02-18 12:00 Aprea Stockholm, Sweden – February 18, 2010. Aprea, a cancer research and development company, announces today that the European Medicines Agency has adopted a positive opinion recommending Aprea’s drug candidate APR-246 for designation as orphan medicinal product to the European Commission, for the treatment of acute myeloid leukemia (AML).

2009-05-14 15:24 Aprea Stockholm, Sweden – Aprea announced today that the Swedish Medical Products Agency has approved the start of a Phase I clinical trial with Aprea’s candidate drug, APR-246. Scheduled to begin during May 2009, the Phase I-study includes patients with refractory hematologic malignancies or prostate carcinoma.